Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan.
Anticancer Res. 2011 Mar;31(3):763-9.
BACKGROUND/AIM: Photodynamic therapy (PDT) is an attractive, minimally invasive modality for cancer therapy that utilizes the interaction of light and photosensitizer. To improve the efficacy of PDT, development of cancer specificity of the photosensitizer is needed. Cancer cells consume more glucose than normal cells. In this study, the efficacy of PDT using a newly developed photosensitizer, glycoconjugated chlorin (H2TFPC-SGlc), was compared with Talaporfin, which is clinically used in Japan.
Photosensitizers were administered to gastric and colon cancer cell lines, followed by irradiation of light, and the cell death-inducing effects were compared. Xenograft tumor mouse models were established and photosensitizer accumulation was assessed and antitumor effects analyzed.
In vitro, H(2)TFPC-SGlc was 30 times more cytotoxic to cancer cells than was Talaporfin. In vivo, H(2)TFPC-SGlc accumulation was higher in xenograft tumors and significantly suppressed tumor growth when compared with Talaporfin.
This novel glycoconjugated chlorin is potentially useful in PDT.
背景/目的：光动力疗法（PDT）是一种有吸引力的、微创的癌症治疗方法，利用光和光敏剂的相互作用。为了提高 PDT 的疗效，需要开发具有癌症特异性的光敏剂。癌细胞比正常细胞消耗更多的葡萄糖。在这项研究中，比较了新开发的糖缀合叶绿素（H2TFPC-SGlc）与日本临床使用的 Talaporfin 作为光敏剂进行 PDT 的疗效。
将光敏剂施用于胃和结肠癌细胞系，然后进行光照照射，比较细胞死亡诱导效果。建立异种移植肿瘤小鼠模型，评估光敏剂的积累并分析抗肿瘤作用。
体外实验中，H(2)TFPC-SGlc 对癌细胞的细胞毒性比 Talaporfin 高 30 倍。在体内，H(2)TFPC-SGlc 在异种移植肿瘤中的积累更高，并与 Talaporfin 相比，显著抑制肿瘤生长。
这种新型糖缀合叶绿素在 PDT 中具有潜在的应用价值。
